Ren Jianan, Tao Qingsong, Wang Xinbo, Wang Zhiming, Li Jieshou
Department of General Surgery, Jinling Hospital, Nanjing, 210002, PR China.
Dig Dis Sci. 2007 Aug;52(8):1790-7. doi: 10.1007/s10620-007-9747-y. Epub 2007 Apr 5.
To date few therapies have been shown to reliably prevent the evolution of Crohn's disease (CD). The traditional Chinese medicine, Tripterygium wilfordii Hook F (TWHF), has both immunomodulatory and anti-inflammatory activities. Our aim was to investigate the potential efficacy of T2, the major constituent of extracts of TWHF, in inducing remission of active CD. Twenty adult patients with active CD were enrolled to be treated with T2 pills (60 mg daily) for 12 weeks. Plasma levels of C-reactive protein (CRP), tumor necrosis factor (TNF)-alpha, and interleukin (IL)-1beta were measured at entry and every 2 weeks thereafter until week 12. At each visit the CD Activity Index (CDAI) was calculated. The CD Endoscopic Index of Severity was measured at entry and week 12. Sixteen patients completed the study. A significant decrease in serum levels of CRP, TNF-alpha, and IL-1beta occurred rapidly after commencement of treatment. CDAI scores showed a rapid decline during the first 8 weeks and reached their lowest at week 10. Endoscopic improvements were observed at week 12. In conclusion, T2 appears to be effective for the treatment of mildly or moderately active CD. Further controlled studies are warranted for this promising drug.
迄今为止，几乎没有疗法被证明能可靠地预防克罗恩病（CD）的进展。中药雷公藤（Tripterygium wilfordii Hook F，TWHF）具有免疫调节和抗炎活性。我们的目的是研究TWHF提取物的主要成分T2诱导活动性CD缓解的潜在疗效。招募了20名成年活动性CD患者，给予T2丸剂（每日60毫克）治疗12周。在入组时及之后每2周直至第12周测量血浆C反应蛋白（CRP）、肿瘤坏死因子（TNF）-α和白细胞介素（IL）-1β水平。每次就诊时计算CD活动指数（CDAI）。在入组时和第12周测量CD内镜严重程度指数。16名患者完成了研究。治疗开始后，血清CRP、TNF-α和IL-1β水平迅速显著下降。CDAI评分在最初8周迅速下降，在第10周达到最低。在第12周观察到内镜改善。总之，T2似乎对轻度或中度活动性CD有效。对于这种有前景的药物，有必要进行进一步的对照研究。
